XHKG
6609
Market cap137mUSD
May 09, Last price
28.00HKD
1D
0.00%
1Q
14.29%
IPO
-77.05%
Name
Shanghai HeartCare Medical Technology Corp Ltd
Chart & Performance
P/E
—
P/S
3.58
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-0.56%
Rev. gr., 5y
%
Revenues
278m
+19.61%
Net income
-14m
L-85.51%
CFO
0k
P
Earnings
May 20, 2025
Profile
Shanghai HeartCare Medical Technology Corporation Limited engages in the research, development, manufacture, and sale of neuro-interventional medical devices worldwide. The company offers ischemic stroke thrombectomy, intracranial stenosis treatment, ischemic stroke prevention, hemorrhagic stroke treatment, and vascular access devices. Its products are used for the treatment and prevention of ischemic stroke, including acute ischemic stroke and intracranial stenosis, as well as for the treatment of hemorrhagic stroke. The company was formerly known as Shanghai Care Medical Technology Corporation Limited. Shanghai HeartCare Medical Technology Corporation Limited was incorporated in 2016 and is headquartered in Shanghai, the People's Republic of China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | 277,899 19.61% | 232,344 26.94% | 183,032 103.17% | |||
Cost of revenue | 292,928 | 346,298 | 380,385 | |||
Unusual Expense (Income) | ||||||
NOPBT | (15,029) | (113,954) | (197,353) | |||
NOPBT Margin | ||||||
Operating Taxes | 1,630 | (8,908) | (865) | |||
Tax Rate | ||||||
NOPAT | (16,659) | (105,046) | (196,488) | |||
Net income | (13,622) -85.51% | (94,012) -53.08% | (200,384) 2.33% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | (12,748) | (42,756) | ||||
BB yield | 1.13% | 3.04% | ||||
| Debt | ||||||
Debt current | 7,669 | 4,911 | 10,878 | |||
Long-term debt | 63,827 | 67,855 | 85,496 | |||
Deferred revenue | 30,407 | |||||
Other long-term liabilities | 33,497 | 34,347 | ||||
Net debt | (651,698) | (650,898) | (774,148) | |||
| Cash flow | ||||||
Cash from operating activities | (88,406) | (266,770) | ||||
CAPEX | (49,313) | (37,237) | ||||
Cash from investing activities | (125,453) | 44,838 | ||||
Cash from financing activities | (21,485) | (24,753) | ||||
FCF | 5,585 | (149,510) | (349,821) | |||
| Balance | ||||||
Cash | 713,720 | 721,139 | 870,122 | |||
Long term investments | 9,474 | 2,525 | 400 | |||
Excess cash | 709,299 | 712,047 | 861,370 | |||
Stockholders' equity | 1,107,700 | (602,346) | (338,452) | |||
Invested Capital | 422,194 | 1,748,720 | 1,583,654 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 37,768 | 38,077 | 38,271 | |||
Price | 21.95 -26.22% | 29.75 -19.05% | 36.75 -64.42% | |||
Market cap | 829,017 -26.82% | 1,132,795 -19.46% | 1,406,471 -59.23% | |||
EV | 177,319 | 481,897 | 632,323 | |||
EBITDA | (15,029) | (81,695) | (165,566) | |||
EV/EBITDA | ||||||
Interest | 2,158 | 2,149 | ||||
Interest/NOPBT | ||||||